History of clinically significant coagulation or platelet disorder in the past  months.
Clinically significant bleeding event, as judged by investigator, within prior  months
History of thromboembolism within the past  years, history of catheter-related thrombophlebitis or other clinically significant thrombophlebitis are excluded.
The patient has any pre-existing coagulopathy, recent hemoptysis, gross hematuria, or gastrointestinal bleeding, and a history of a clinically significant cardiovascular or cerebrovascular event within  months prior to study entry
Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within  months of start of study drug
History of clinically significant hemorrhagic or thromboembolic event in the past  months
Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within  months of registration
History of clinically significant hemorrhagic or thromboembolic event in the past  months
History of clinically significant hemorrhagic or thromboembolic event in the past  months
History of clinically significant bleeding
Subjects with history of known bleeding disorder(s) or history of clinically significant hemorrhage (e.g., gastrointestinal , neurologic), within the past  months.
Participants with history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within  months of start of study drug
History of active clinically significant bleeding
History of clinically significant hemorrhagic or thrombotic event within the past  months, not including uncomplicated catheter-associated venous thrombosis; patients on anti-coagulation are not permitted to be on any oral formulations (warfarin, rivaroxaban, dabigatran, etc.) due to concern for drug-drug interaction
Have active, acute, or chronic clinically significant infections or bleeding within the last  months or previous thromboembolic or hemorrhagic events during anti angiogenic therapy.
History of clinically significant hemorrhagic or thromboembolic event in the past  months
History of clinically significant hemorrhagic or thromboembolic event in the past  months
Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within  months of start of study drug
History of previous clinically significant GI bleed in the last  months prior to first dose
History of clinically significant bleeding episodes
History of clinically significant bleeding within  months of enrollment/randomization
Patients must not have a known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past
History of clinically significant hemorrhagic or thromboembolic event in the past  months
Participants with history of clinically significant bleeding, specifically any history of intracranial hemorrhage/hemorrhagic cardiovascular accident (CVA), or participants with gastrointestinal bleeding within the  months prior to study entry
Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within  months of start of study drug.
History of clinically significant bleeding within  months of enrollment/randomization
History of clinically significant haemoptysis within the past  months
History of major thrombotic or clinically relevant major bleeding event in the past  months
History of clinically significant coagulation or platelet disorder in the past  months